{"id":23807,"date":"2023-09-22T17:26:53","date_gmt":"2023-09-22T15:26:53","guid":{"rendered":"https:\/\/www.izb-online.de\/izb-biotech-news-atriva-therapeutics-meldet-exklusive-absichtserklaerung-fuer-reverse-takeover-transaktion-mit-biocure-technology-innovations-und-gruenderzentrum-biotechnologie-izb\/"},"modified":"2023-09-22T17:34:44","modified_gmt":"2023-09-22T15:34:44","slug":"izb-biotech-news-atriva-therapeutics-announces-exclusive-letter-agreement-for-reverse-takeover-transaction-with-biocure-technology-innovations-und-gruenderzentrum-biotechnologie-izb","status":"publish","type":"post","link":"https:\/\/www.izb-online.de\/en\/izb-biotech-news\/atriva-therapeutics-announces-exclusive-letter-agreement-for-reverse-takeover-transaction-with-biocure-technology-innovations-und-gruenderzentrum-biotechnologie-izb\/","title":{"rendered":"Atriva Therapeutics Announces Exclusive Letter Agreement for Reverse Takeover Transaction with Biocure Technology"},"content":{"rendered":"

[vc_row el_class=”gco-magazine-container”][vc_column el_class=”bildspalte”][vc_row_inner][vc_column_inner offset=”vc_col-lg-12 vc_col-md-12″][vc_column_text el_class=”gco-magazine–title”]<\/p>\n

Atriva Therapeutics Announces Exclusive Letter Agreement for Reverse Takeover Transaction with Biocure Technology<\/h1>\n

[\/vc_column_text][vc_column_text el_class=”gco-magazine-lead”]This agreement marks a significant step forward in Atriva`s commitment to combating severe RNA virus infections through innovative host-cell-targeting therapies.[\/vc_column_text][vc_column_text el_class=”gco-magazine–post-date”]September, 2023[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner][vc_single_image image=”23805″ img_size=”full”][vc_column_text el_class=”gco-magazine-copyright”]\u00a9 Shutterstock \/ William Potter[\/vc_column_text][vc_column_text el_class=”gco-magazine-picture-discription”]<\/p>\n

National flag of Canada with a large display of the daily exchange price and quotations during normal economic hours.<\/p>\n

[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine–quote” css=”.vc_custom_1611310713611{margin-top: 33px !important;}”][vc_column_inner][vc_column_text]<\/p>\n

\u201eWe are eager to embark on this journey and combine the strengths of both companies. Together, we aim to address the urgent medical need for safe and effective therapies for patients suffering from severe RNA virus infections.\u201c<\/h6>\n

Christian Pangratz, Chief Executive Officer of Atriva<\/p>\n

[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine-container–copy” css=”.vc_custom_1591795890737{margin-top: 21px !important;}”][vc_column_inner][vc_column_text]Upon transaction completion, Atriva shareholders and concurrent financing subscribers will collectively hold not less than 75% of the securities of the resulting issuer. Current CURE shareholders will retain a maximum of 25% on a fully diluted basis. The letter agreement stipulates no advances from CURE to Atriva. Atriva will provide CURE with an exclusivity fee of CA$15,000 per month for a minimum of three months. Additionally, a finder’s fee of US$2,000,000 is payable through the issuance of CURE shares, with pricing to be determined, aligning with concurrent private placement terms.<\/p>\n

“We are delighted to have entered into this exclusive letter agreement with Biocure. Our discussions with the Biocure management and board of directors have been exceptionally productive and constructive. We are eager to embark on this journey and combine the strengths of both companies. Together, we aim to address the urgent medical need for safe and effective therapies for patients suffering from severe RNA virus infections. This agreement marks a significant milestone in our commitment to advancing innovative solutions for the benefit of global healthcare.”, said Christian Pangratz, Chief Executive Officer of Atriva.<\/p>\n

Transaction Conditions:
\nThe completion of the Transaction is contingent upon various terms and conditions, including the successful completion of due diligence, the execution of a definitive agreement by November 30, 2023, (inclusive of typical transaction elements), and the successful completion of a private placement by Atriva or CURE to raise gross proceeds of at least US$15,000,000. Additionally, approval from both companies’ shareholders and the endorsement of the CSE and other relevant regulatory authorities are essential prerequisites for finalization.<\/p>\n

“This letter agreement underscores our commitment to leverage this transaction with CURE as an attractive growth option for Atriva and its stakeholders. We are enthusiastic about the prospect of our companies joining forces and continuing to contribute to improving pandemic preparedness on an extended international scale.” stated Ulrich Dauer, PhD, Chairman of the Advisory Board of Atriva.<\/p>\n

For additional information on this transaction, please visit https:\/\/biocuretech.com\/news<\/a>.<\/p>\n

About Atriva Therapeutics
\n<\/strong>Atriva Therapeutics\u2019 mission is to develop an antiviral therapy platform against severe respiratory and systemic diseases with a high unmet medical need induced by RNA viruses, e.g., influenza and COVID-19. The clinical-stage biopharmaceutical company is pioneering the development of host-targeting antiviral therapies, making development of viral resistance unlikely, and thereby significantly contributing to pandemic preparedness. The Atriva lead product zapnometinib (ATR-002) is a first-in-class, host-targeting agent that aims to inhibit viral replication and to favorably modulate the body\u2019s immune response to RNA viruses. Atriva Therapeutics was founded in 2015 in T\u00fcbingen by a team of leading scientists in viral research and seasoned industry experts and is based with its administrative\/operations office in Martinsried (near Munich), Germany.<\/p>\n

About Biocure
\n<\/strong>Biocure owns approximately 45% stakes of BiocurePharm in Korea who is a leading biotech company developing its CAR-T cell therapy for leukemia, lung, breast and pancreatic cancer. BiocurePharm is in the process of pre-clinical trials of three major biosimilar products in South Korea, including Interferon Beta 1b, PEG- Filgrastim as well as Ranibizumab. Interferon Beta 1b is used for treating relapsing forms of multiple sclerosis (\u201cMS\u201d). Filgrastim is used to treat neutropenia, a lack of certain white blood cells caused by bone marrow transplants, chemotherapy, and other conditions. Ranibizumab is used for treating macular degeneration. It is also used to treat a type of eye problem known as macular edema, as well as certain eye problems caused by diabetes.<\/p>\n

For further information, please visit www.atriva-therapeutics.com<\/a> and follow us on LinkedIn<\/a> and X (formerly Twitter<\/a>).[\/vc_column_text][vc_column_text css=”.vc_custom_1583761043671{background-color: #1e73be !important;}” el_class=”redaktionell”][\/vc_column_text][\/vc_column_inner][\/vc_row_inner]\n\n

\n \n